je.st
news
Tag: medicine
Catching counterfeit medicine at airports
2017-09-14 09:00:00| Airport Technology
Counterfeit medicine rakes in around $200bn a year globally and airports are a crucial link as these illegal and often dangerous drugs transit across borders. So what can airport staff do to cut the supply chain of illegal, life-threatening drugs?
Tags: medicine
airports
catching
counterfeit
UK invests 146m in medicine research
2017-08-30 10:50:22| BBC News | Business | UK Edition
The UK government is investing 1bn over the next four years in boosting science and technology.
Tags: research
medicine
invests
146m
How antibiotic overuse in human medicine impacts beef producers
2017-06-23 01:11:01| Beef
While animal agriculture is the focus of antibiotic-resistant bacteria in people, the human use of antibiotics must be considered as well. Fourth of a six-part series.
Tags: human
medicine
producers
impacts
Merck Scientists Publish New Research Detailing the Early Development of Verubecestat, an Investigational BACE1 Inhibitor in Science Translational Medicine
2016-11-02 21:30:00| Merck.com - Research & Development News
Dateline City: KENILWORTH, N.J. Results of First Phase 3 Trial Anticipated in Late 2017 KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced the publication of research conducted by Merck scientists on the discovery and development of verubecestat, an investigational small molecule inhibitor of the enzyme beta-site amyloid precursor protein cleaving enzyme 1 (BACE1), for the potential treatment of Alzheimers disease (AD). Language: English Contact: MerckMedia:Pam Eisele, 267-305-3558orIan McConnell, 908-740-1921orInvestors:Teri Loxam, 908-740-1986orAmy Klug, 908-740-1898 Ticker Slug: Ticker: MRK Exchange: NYSE read more
Tags: research
development
science
early
Merck Announces Pivotal Phase 3 Study of Letermovir, an Investigational Antiviral Medicine for Prevention of Cytomegalovirus (CMV) Infection in High-Risk Bone Marrow Transplant Patients, Met Primary Endpoint
2016-10-19 13:00:00| Merck.com - Corporate News
Dateline City: KENILWORTH, N.J. KENILWORTH, N.J.--(BUSINESS WIRE)--Merck & Co., Inc. (NYSE: MRK), known as MSD outside the United States and Canada, today announced that the pivotal Phase 3 clinical study of letermovir, an investigational antiviral medicine, met its primary endpoint. Language: English Contact: MerckMedia:Pam Eisele, 267-305-3558Robert Consalvo, 908-236-1127orInvestors:Teri Loxam, 908-740-1986Amy Klug, 908-740-1898 Ticker Slug: Ticker: MRK Exchange: NYSE read more
Tags: met
study
primary
medicine
Sites : [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] next »